|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
A missense mutation was found at T1796A (V599E) in exon 15 in four of the six cell lines and 51 of 207 thyroid tumors (24.6%; 0 of 20 follicular adenoma, 0 of 11 follicular carcinoma, 49 of 170 papillary carcinomas, and 2 of 6 undifferentiated carcinomas).
|
12970315 |
2003 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data clearly confirm that BRAF(V599E) is the more common genetic alteration found to date in adult sporadic PTCs, that it is unique for this thyroid cancer histotype, and that it might drive the development of PTCs of the classic papillary subtype.
|
15126572 |
2004 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We isolated genomic DNA from primary thyroid tumors and paired lymph node metastases and performed direct sequencing of exon 15 of the BRAF gene mutation that carries the T1799A mutation.
|
15998781 |
2005 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF(V600E) mutation was detected in tumour samples from 31 of 60 conventional micro-PTC patients (52%), but was not detected in patients with other types of thyroid tumours.
|
16268813 |
2005 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF provides signals crucial for proliferation of thyroid carcinoma cells spontaneously harboring the (V600E)BRAF mutation and, therefore, BRAF suppression might have therapeutic potential in (V600E)BRAF-positive thyroid cancer.
|
16533790 |
2006 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In Korea, most thyroid cancer is the classic papillary type and the BRAF(V600E) mutation is highly prevalent.
|
17054470 |
2006 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
They also potently blocked MEK phosphorylation in human thyroid cancer cell lines with either RET/PTC1 (TPC1) or BRAF(V600E) (NPA, ARO, and FRO) mutations.
|
16551863 |
2006 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation status was determined in 347 tumor samples from 314 patients with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid cancer, and 29 with the follicular variant of papillary thyroid cancer).
|
17717450 |
2007 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Small molecule inhibitors that selectively target B-Raf(V600E) may provide clinical benefit for patients with thyroid cancer.
|
17363500 |
2007 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dideoxy sequencing is the most commonly used method for detecting the BRAF(V600E) mutation in thyroid cancer and melanoma.
|
18462259 |
2009 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In many cancers, including thyroid cancer, B-Raf(V600E) appears to play a crucial role in cell proliferation, survival and de-differentiation.
|
19356676 |
2009 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results in thyroid cancer cells, namely those harbouring BRAF(V600E) mutation showed that BRAF signalling pathway provides important proliferation signals.
|
19878585 |
2009 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We developed an allele-specific real-time PCR method for the detection of BRAF(T1799A) in blood samples and studied prospectively blood samples from 193 patients with thyroid cancer (173 PTC, 20 non-PTC) attending for routine follow-up.
|
19850689 |
2009 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720.
|
20498063 |
2010 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
While BRAF(V600E) is a highly specific marker of thyroid cancer, RET rearrangements have been disclosed also in non malignant thyroid lesions and their biological significance is debated.
|
21048359 |
2010 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
A literature search using PubMed identified all the pertinent literature on the identification and utilization of the B-Raf(V600E) mutation in thyroid cancer.
|
20637346 |
2010 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mice with BRAF(V600E)-induced PTC will provide an excellent system to study thyroid tumor initiation and progression and the evaluation of inhibitors of oncogenic BRAF signaling.
|
21512141 |
2011 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032 and demonstrated its specific potential as an effective and BRAF(T1799A) mutation-selective therapeutic agent for thyroid cancer.
|
21185263 |
2011 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.
|
21447745 |
2011 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, regulation of AMPK activity may be potentially useful as a therapy for th</span>yroid cancer</span> if the cancer harbors a BRAF V600E mutation.
|
21795305 |
2011 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we have shown that PLX4720 preferentially inhibits migration and invasion of B-Raf(V600E) thyroid cancer cells and tumor aggressiveness.
|
21355020 |
2011 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Identification of BRAF(V600E) in thyroid neoplasia may be useful because it is specific for malignancy, connotes a worse prognosis, and is the target of novel therapies currently under investigation.
|
22997209 |
2012 |
|
rs113488022
|
|
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Polymerase chain reaction was used to amplify exon 15 of the BRAF gene from paraffin-embedded thyroid tumor specimens, followed by direct sequencing to detect the BRAF(V600E) mutation.
|
22190222 |
2012 |